FGP
CSTL icon

Freestone Grove Partners’s Castle Biosciences CSTL Stock Holding History

Freestone Grove Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24 Buy
+1
New +$22 ﹤0.01% 959

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's CSTL Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Castle Biosciences (CSTL) in Q2 2026: 1 share worth $24. The stake represents ﹤0.01% of the portfolio and ranks #959 among its holdings.

177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Freestone Grove Partners held 1 share of Castle Biosciences worth $24 as of Q2 2026.
  • Castle Biosciences was a new Freestone Grove Partners position in Q2 2026.
  • Castle Biosciences made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #959 holding.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.